Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.

Abstract

PURPOSE:

To report the short-term effects of intravitreal bevacizumab in patients with type 2 idiopathic macular telangiectasia (IMT).

DESIGN:

Noncomparative, interventional, retrospective case series.

PARTICIPANTS:

Seven eyes of 6 patients with type 2 IMT were studied.

METHODS:

Patients received 2 doses of intravitreal bevacizumab (1.5 mg) at 4-week intervals. Serial examinations included standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA), fluorescein angiography, and optical coherence tomography (OCT).

MAIN OUTCOME MEASURES:

Assessments of OCT retinal thickness, angiographic characteristics, and VA were performed at baseline and at 4 and 8 weeks after the initial treatment.

RESULTS:

A mean increase in VA of 8 ETDRS letters at 8 weeks was found (P<0.05). Visual acuity improved by more than 15 letters in 1 patient and by 10 to 15 letters in 2 patients and remained stable (-1 to +10 letters) in another 4 patients compared with baseline. All patients showed a reduction in extension and intensity of late-stage parafoveal hyperfluorescence on fluorescein angiography. In OCT imaging, mean retinal thickness showed a reduction in the foveal and in the parafoveal zones (P<0.01). The most pronounced effect (mean decrease, 22 microm) was in the parafoveal temporal zone. No significant ocular or systemic side effects were observed.

CONCLUSIONS:

Short-term results indicate that inhibition of vascular endothelial growth factor by intravitreal bevacizumab is associated with a decrease in retinal thickness and a reduction in angiographic leakage in type 2 IMT. Furthermore, intravitreal bevacizumab may improve VA in affected patients.

• Authors: Peter Charbel Issa, Frank G Holz, Hendrik P N Scholl
• Journal: Ophthalmology (Ophthalmology) Vol. 114 Issue 9 Pg. 1736-42 (Sep 2007) ISSN: 1549-4713 [Electronic] United States
• PMID: 17822979 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Aged
• Angiogenesis Inhibitors (administration & dosage)
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Capillary Permeability (drug effects)
• Female
• Fluorescein Angiography
• Humans
• Injections
• Male
• Middle Aged
• Retinal Diseases (diagnosis, drug therapy)
• Retinal Vessels (drug effects, pathology)
• Telangiectasis (diagnosis, drug therapy)
• Tomography, Optical Coherence
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (drug effects)
• Vitreous Body